
The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations within and outside of Duke, the Ferrari Lab has expanded its focus of research to include the ontogeny of HIV-1 specific immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates.
Education and Training
- M.D., University of Genoa (Italy), 1985
In the News
- Global List of Highly Cited Puts Duke in Top TenNovember 19, 2019
- Duke Faculty Plentiful On ‘Highly Cited’ ListNovember 27, 2018
Selected Grants
- Interdisciplinary Research Training Program in AIDS
- EQAPOL - Years 2017 to 2024 - BASE
- Infectious Diseases in Africa: Correlates of Protection, Lessons from Vaccines and Natural Infection Studies
- Eqapol Opt 3 -2020-2021
- CIVICS Component A - Option 1
- Targeting the HIV-1 reservoir with a combination of an IDLV-SIVGag therapeutic vaccine and Fc-engineered bnAbs (R01)
- Combined Hepatitis B and HIV-1 Envelope Infant Vaccination to Augment T cell Help through Enhanced Linked Recognition
- CARE Focus 1: Latency Biomarker Project
- CARE Focus 2: Clearance of HIV Antigen-Positive Cells
- MGD020 IND enabling studies
- Primate Contract Expansion for Covid-19
- Nonhuman Primate Option 2
- 14th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST 2020)
- Targeting Apoptosis and Immune Control of Epstein-Barr Virus Infected Tonsillar B Cells
- Project 2: Synthetic DNA & Novel Env Vaccine for HIV
- HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
- Protocol Development Assays
- HVTN Laboratory Center: HVTN Phase 1
- HVTN Laboratory Center: HVTN 118
- Impact of Fc N-glycan structure on HIV-specific antibody functions
- 13th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (Interest)
- Infectious Diseases in Africa: Immune Escape and HIV Vaccines
- Exploring Dual-Affinity Re-Targeting Proteins for Cure of Pediatric HIV-1 Infection
- Creation of a bnAbnectin
- IGM Proposal
- 2018 INTEREST Conference
- HIV Vaccine Trials Network: LC P5 PF
- HVTN - A004
- Evaluation of the host immune response and viral molecular phenotype in lung transplant recipients with PTLD
- CARE Duke-UNC Latency Biomarker Supplement Year 2
- 2017 INTEREST Conference
- Nonhuman Primate Core-Option 6
- EQAPOL - Option 6 - 2016 to 2017 - ELISPOT
- EQAPOL Option 5
- Focus 1: Detection of HIV Antigen-Positive Cells
- Invitro Function of DART Molecules (Base)
- Infant immune correlates of perinatal mother to child transmission of HIV
- Intervening with Latent HIV-1 Infection using Gnidimacrin
- 10th INTEREST Workshop on HIV
- HIV Vaccine Trials Network: LC P5 PF
- LC: HIV Vaccine Trials Network: Phase 1 PF
- HIV Envelope-specific functional antibody responses in HIV-exposed, HIV-vaccinated infants
- HIV-1 Gene Suppression by CD8+ T Cells
- AIDS International Training and Research Program
- Poly-functional analyses of vaccine-induced T cell responses
- Correlates of Vaccine Protection Workshop
- International Clinical Trials Unit
- Infectious Diseases in Africa: Measurement of Immune Responses
- Central Laboratory for the HIV Vaccines Trial Network
- NCRR FACSAria Cell Sorter
- Anti-Hiv Ctl And Hiv Suppressive Cd8 Cells
- Anti-Hiv Ctl And Hiv-Suppresive Cd8+ Cells
- Anti-Hiv Ctl And Hiv Suppresive Cd8+ Cells
- Antihiv Ctl And Hiv Suppressive Cd8 Cells